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Abstract
Introduction Data on postoperative bile reflux after one anastomosis gastric bypass (OAGB) is lacking. Bile reflux scintigraphy
(BRS) has been shown to be a reliable non-invasive tool to assess bile reflux after OAGB. We set out to study bile reflux after
OAGB with BRS and endoscopy in a prospective series (RYSATrial).
Methods Forty patients (29 women) underwent OAGB between November 2016 and December 2018. Symptoms were reported
and upper gastrointestinal endoscopy (UGE) was done preoperatively. Six months after OAGB, bile reflux was assessed in UGE
findings and as tracer activity found in gastric tube and esophagus in BRS (follow-up rate 95%).
Results Twenty-six patients (68.4%) had no bile reflux in BRS. Twelve patients (31.6%) had bile reflux in the gastric pouch in
BRS and one of them (2.6%) had bile reflux also in the esophagus 6 months postoperatively. Mean bile reflux activity in the
gastric pouch was 5.2% (1–21%) of total activity. De novo findings suggestive of bile reflux (esophagitis, stomal ulcer, foveolar
inflammation of gastric pouch) were found for 15 patients (39.5%) in postoperative UGE. BRS and UGE findings were
significantly associated (P = 0.022). Eight patients experienced de novo reflux symptoms at 6 months, that were significantly
associated with BRS and de novo UGE findings postoperatively (P = 0.033 and 0.0005, respectively).
Conclusion Postoperative bile reflux in the gastric pouch after OAGB is a common finding in scintigraphy and endoscopy. The
long-term effects of bile exposure will be analyzed in future reports after a longer follow-up.
Trial registration Clinical Trials Identifier NCT02882685
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Introduction
The bariatric surgery community has seen a rise of one anas-
tomosis gastric bypass (OAGB) during the last years. In 2016,
OAGB was the third most common bariatric operation consti-
tuting 4.8% of all primary operations after sleeve gastrectomy
(53.6%) and Roux-en-Y gastric bypass (RYGB) (30.1%) [1].
According to the 5th IFSO registry report of 2019, OAGB
constituted 3.7% of all primary bariatric procedures. Many
reports have shown excellent weight loss results after
OAGB, but throughout OAGB’s over 20-year history, there
has been a lot of debate on the safety of the procedure [2, 3].
To date, two prospective randomized controlled trials compar-
ing OAGB and RYGB have been published [4, 5]. In a newly
published review of these two trials, Lee et al. concluded that
the controversy of bile reflux requires elucidation after longer
follow-up [6]. Bile reflux has been feared to even cause cancer
in the esophagus or gastric pouch, and it is the main reason
why many surgeons do not perform OAGB procedures ac-
cording to a recent survey [7]. Evidence of carcinogenic effect
of bile reflux after OAGB is lacking, but postoperative de
novo reflux symptoms after OAGB are quite common [3].
Our group published a pilot series on studying bile reflux
with a scintigraphic method in 2017 [8]. We found that bile
reflux can be assessed accurately by using a non-invasive
scintigraphic method. This was also confirmed in a review
in 2018 [9]. Here, we set out to prospectively study bile reflux
with a scintigraphic method (bile reflux scintigraphy, BRS)
and endoscopies in a prospective series as a part of a random-
ized controlled trial comparing OAGB and RYGB (RYSA tri-
al, clinicaltrials.org identifier NCT02882685).
Methods
RYSA trial is a randomized controlled open-label trial of two
academic centers comparing OAGB and RYGB. Entire RYSA
trial design and further end-points will be described in detail in
future reports. Here, we describe one part of the trial that
addresses the issue of bile reflux after OAGB. Forty patients
were included after randomization. All patients underwent
OAGB between November 2016 and December 2018 in an
academic bariatric surgery center. The authors (TS, AJ, HS,
and AP) interviewed all patients preoperatively and also
6 months after OAGB). Body mass index (BMI, kg/m2, cal-
culated as weight/height × height), comorbidities, and gastro-
intestinal symptoms were recorded prior to OAGB and
6 months after.
Surgical Technique
OAGB was performed by the authors (AJ, HS, and AP) under
general anesthesia via a standard 4-port laparoscopy and a
subxiphoidal liver retractor. An approximately 15-cm long
tubular gastric pouch was created along a 38-Fr bougie.
Biliopancreatic limb was measured at 210 cm using a marked
dissector and an antecolic anastomosis was done side-to-side
with a 45-mm stapler. The remaining defect was hand-sewn
with a braided absorbable 2-0 running suture including lateral
antireflux stiches between gastric pouch and afferent loop of
jejunum.Mesenteric defect was not closed. The common limb
length was not measured.
Scintigraphy
Bile reflux scintigraphy (BRS) was done at 6 months with a
method that was described in detail previously [8]. In short,
after 12 h of fasting, an intravenous bile tracer (99mTc-
mebrofenin) was administered, and a 60-min dynamic scan
with a gamma camera immediately followed by a 30-min
SPECT–CT scan was acquired. Using the images of the dy-
namic series, the beginning and the end of bile reflux activity
in the gastric pouch and esophagus were recorded and the
amount of bile reflux was calculated as a ratio of tracer in-
duced maximum count rate per pixel measured in the gastric
pouch or esophagus compared to the maximum count rate per
pixel induced by the tracer in the whole liver. All scintigra-
phies were quantified by a physicist (TI) and analyzed by a
nuclear medicine physician (AL). Examples of gamma cam-
era images and SPECT–CT scan are shown in Fig. 1 and
Fig. 2, respectively.
Endoscopy
Upper gastrointestinal endoscopy (UGE) was done preopera-
tively and at 6 months. UGE was done without sedation using
a flexible endoscope (Olympus Q190, Tokyo, Japan).
Biopsies and photographs were obtained from the jejunum,
anastomosis, gastric pouch, gastro-esophageal junction, and
esophagus. All endoscopies were done by the authors (TS,
AJ, HS, and AP).
Ethical Approval
The trial was reviewed by the operative ethical committee of
our institution and approved by scientific boards of both aca-
demic centers participating in the study. The study was carried
out according to the Helsinki Declaration and informed con-
sent was obtained for all patients.
Statistical Analysis
All variables are expressed as mean (min–max) with percent-
ages where applicable. The Fischer’s exact test was used to
analyze dependence of categorical variables in contingency
tables. Associations between categorical and continuous
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variables with BRS and UGE findings were analyzed with the
binary logistic regression and one-sample T test, respectively.
P value less than 0.05 was considered statistically significant.
Results
Forty patients were included in this study after randomization
into the OAGB group. Patient demographics are given in
Table 1.
Thirty-eight patients (95%) underwent BRS at 6 months.
For 26 patients (68.4%), BRS did not show any sign of bile
reflux into the gastric pouch or esophagus. Twelve patients
(31.6%) had a positive BRS, 11 (28.9%) had bile reflux activ-
ity only in the gastric pouch, and one patient (2.6%) had bile
reflux activity also in the esophagus at the end of the SPECT–
CT scan (Fig. 2). Bile reflux activity began in the gastric
pouch at 36.2 min (16–54). The highest activity during the
dynamic series of BRS was at 50.2 min (38–60). Bile reflux
activity did not completely stop by the end of the 90-min scan
Fig. 2 SPECT–CTscan at the end of bile reflux scintigraphy of a representative patient. Bile tracer activity in the gastric pouch and esophagus are shown
Fig. 1 Dynamic gamma camera images of bile reflux scintigraphy. Images of a representative patient show bile tracer in the gastric pouch beginning at
51 min after intravenous administration of bile tracer (99mTc-mebrofenin)
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in any of the positive scintigraphies. Mean activity was 5.2%
(1–21%) of total activity. For one patient, the amount of bile
reflux activity could not be calculated. Figure 3 illustrates the
amount of bile tracer activity during the dynamic scan in the
gastric pouch and in the liver of one representative patient.
UGE was done for all 40 patients preoperatively and for 38
patients (95%) at 6 months. UGE findings are summarized in
Table 2. Four patients (10.5%) had an anastomotic ulcer and
two more patients had an erosive inflammation at the anasto-
mosis. Five patients (13.2%) had de novo histologic inflam-
mation or foveolar hyperplasia in the gastric pouch. However,
these five endoscopies were considered macroscopically nor-
mal. Nine patients (23.7%) had an abnormal finding in the
cardia and six patients (15.8%) had de novo esophagitis. Of
these, only one esophagitis was macroscopically evident (Los
Angeles grade A esophagitis). Altogether, 15 patients (39.5%)
had a new abnormal postoperative finding in UGE.
Eight patients (21.1%) had a positive BRS and a new ab-
normal finding in postoperative UGE, whereas 19 patients
(50%) had neither bile reflux in BRS nor any new findings
in postoperative UGE (P = 0.022).
Nine patients (22.5%) experienced reflux symptoms at
6 months. Five of them had similar symptoms preoperatively.
Four patients (10%) experienced eating difficulties at
6 months. Altogether, eight patients (20%) experienced de
novo symptoms at 6 months. Six of these patients had histo-
logic esophagitis in UGE and one patient had anastomotic
stricture requiring endoscopic balloon dilation. Five patients
with de novo symptoms had bile reflux activity in the gastric
pouch in BRS. For two patients, BRS was negative. One of
the five symptomatic patients refused to have postoperative
BRS and UGE. Associations between new postoperative
symptoms and BRS findings as well as new abnormal UGE
findings were statistically significant (P = 0.022 and P =
0.0005, respectively). No other tested variable was signifi-
cantly associated with BRS or UGE findings.
Discussion
Our current study is the first prospective study on bile reflux
after OAGB using both endoscopies and scintigraphic evalu-
ations. Our study shows that 31.6% of patients had bile reflux
in the gastric pouch in BRS, and one of these patients even had
bile reflux activity in the esophagus. In our previous pilot
study, we found bile reflux in BRS in 55.6% of patients, but
no bile reflux in the esophagus [8]. In the current study, we
found new abnormal findings in postoperative UGE of 39.5%
of patients. Most of these UGE findings were not evident
macroscopically. Histologic findings of foveolar inflamma-
tion of the anastomosis and gastric pouch as well as gastric
metaplasia and esophagitis are not specific findings of bile
reflux, but may suggest effect of bile exposure in the gastric
pouch and esophagus. These findings may also be at least in
part due to gastro-esophageal reflux. It is possible that these
findings will develop into macroscopic lesions after several
years, and therefore a routine endoscopic follow-up is manda-
tory in all prospective trials. Keleidari et al. compared bile
reflux frequencies after OAGB and RYGB. They used a
Sydney system for classifying histological findings of UGE
and self-reported reflux symptoms. They found bile reflux
symptoms and a positive bile reflux index in 7.8% and UGE
Table 1 Patient demographics
Preop 6 mo
Number of patients 40
Women 29 (72.5%)
Age, y 44.4 (28.4–58.6)
BMI, kg/m2 45.2 (35.4–62.0) 35.2 (26.3–49.6)
Comorbidities
DM 14 (35%) 6 (15%)
Duration, y 6.7 (0.5–20.0)
Oral medication only 10 (25%) 5 (12.5%)
Insulin 4 (10%) 1 (2.5%)
HTA 22 (55%) 16 (40%)
Dyslipidemia 10 (25%) 9 (22.5%)
OSAS 18 (45%) 9 (22.5%)
Arthrosis symptoms 19 (47.5%) 12 (32.5%)
Symptoms
Reflux 6 (15%) 9 (22.5%)
Eating problems 0 4 (10%)
BMI, body mass index; Preop, prior to bariatric surgery; 6 mo, 6 months after bariatric surgery; y, years; kg,
kilograms; m, meters; DM, type 2 diabetes; HTA, hypertension; OSAS, obstructive sleep apnea
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findings suggestive of bile reflux in 4.8% of OAGB patients.
These findings were not statistically different compared to the
RYGB group, and they concluded that bile reflux is as often
encountered after OAGB and RYGB [10]. However, the
Sydney system is not intended for postoperative assessment,
and it should include biopsies of the antrum, which cannot be
obtained after bariatric bypass surgery [11]. Also, the findings
of Keleidari et al. are not supported by the findings of the
YOMEGA trial, where bile was found in the gastric pouch
of 16% of patients after OAGB and none after RYGB [4].
In our study, postoperative UGE findings and BRS findings
were significantly associated. Also, reflux symptoms were
significantly associated with both BRS and postoperative
UGE findings. We found new symptoms in 20% of patients.
These symptoms are not specific for bile reflux and can also
be due to gastro-esophageal reflux. Similar symptoms have
also been reported after a sleeve gastrectomy in 28.1% of
patients [12]. According to a recent meta-analysis by
Mahawar et al., 0.6–10% of patients had some form of
gastro-esophageal reflux symptoms after OAGB [3].
Measuring bile reflux is difficult, and the only non-invasive
and accurate method is bile reflux scintigraphy [9]. There are
no specific questionnaires to separate symptoms of bile reflux
from gastro-esophageal reflux. According to a recent paper by
Deitel and Rutledge, all postoperative reflux symptoms after
OAGB are easily deemed bile reflux instead of gastro-
esophageal reflux without further tests [13]. On the other
hand, even significant bile reflux after OAGB can be
interpreted as gastro-esophageal reflux. Gastric bile reflux is
also to some extent a physiologic phenomenon. Chen et al.
studied scintigraphies of unoperated patients with a clinically
significant duodenogastric reflux disease (DGR) and healthy
controls. Intragastric bile reflux activity was significantly
higher in patients suffering from DGR, but healthy controls
also had as high as 8% intragastric bile reflux activity in scin-
tigraphies [14].
In light of this evidence, it is fair to say that postoperative
bile reflux in the gastric tube after OAGB is a common finding
with clinical relevance, and it can be objectively measured.
The long-term effects of bile exposure remain to be seen after
a longer follow-up. Patients in this study have been enrolled in
a randomized controlled study, which is planned to have
follow-up for minimum 10 years.
Bariatric societies IFSO and ASMBS have both acknowl-
edged OAGB as an effective bariatric surgery operation; yet,
there is continuous doubt about the adverse effects of OAGB
[15, 16].
Bile acids have a carcinogenic effect on esophageal muco-
sa [17, 18]. Potential carcinogenic risk of postoperative bile
reflux after OAGB has been proposed numerous times.
However, to date, only one known case of esophageal adeno-
carcinoma after OAGB has been reported [19]. Notably, the
patient did not have preoperative endoscopy and the carcino-
ma was detected already at 1.5 years after OAGB; hence, it is
unlikely that the carcinoma developed due to de novo bile
reflux after OAGB. Even if there has not been evidence of
carcinogenesis after OAGB, bile reflux can cause debilitating
symptoms and mandate a reoperation. The recent YOMEGA
trial showed serious adverse effects after OAGB, especially
malnutrition and also bile reflux. Two patients (1.6%) required
conversion to RYGB due to intractable bile reflux [4].
All bariatric surgery techniques have their pros and cons. In
this paper, we have not reported the desired outcomes after
OAGB, which will be described in detail in future papers
Fig. 3 Time activity curve of the
dynamic series of a bile reflux
scintigraphy. Bile tracer activity
in the liver (yellow line) and in the
gastric pouch (red line) of one
representative patient is shown. A
subsequent rise in the tracer
activity is seen in the gastric tube
and in the liver. This is most likely
due to reuptake of bile acids
through enterohepatic circulation
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regarding this current trial. The decision to undergo bariatric
surgery and the chosen technique should always be based on
careful consideration of the risks and benefits and the patients
should be informed accordingly. Adequate follow-up, includ-
ing endoscopies, when needed, is of utmost importance.
Our current study has several strengths. It is the first pro-
spective study to objectively study bile reflux with a scinti-
graphic method and endoscopy before and after OAGB. The
follow-up rate is 95%, and all patients were evaluated clini-
cally and endoscopically by a small team of surgeons. The
scintigraphic method is a well-documented, non-invasive,
and accurate tool for objective assessment of bile reflux.
As weaknesses can be mentioned that the study population
is fairly small, and the follow-up time is still short. We did not
use a symptom questionnaire because, to our knowledge, there
is no questionnaire specifically validated for bile reflux symp-
toms. The authors interviewed all our patients, and therefore
the symptoms are reliably reported. The scintigraphic method
can also be criticized, because it only provides a short view of
bile flow through the intestine, and we did not perform BRS
preoperatively. The amount of bile reflux calculated from the
dynamic images was approximate, as the measurements were
based on planar images and overlapping intestinal or back-
ground activity and signal attenuation may disrupt the analy-
sis. In the future, it would be feasible to calculate the actual
tracer activity (in Bq) within the suspected reflux volume on
the three-dimensional SPECT-CT images and compare it di-
rectly to the administered activity (in Bq).
Conclusion
Bile reflux in the gastric pouch after OAGB is a com-
mon finding in scintigraphy and endoscopy. We found
evidence of bile reflux in the gastric pouch in roughly
one third of patients, with one case of esophageal bile
reflux. Endoscopic findings were mostly in the gastric
pouch, and macroscopic lesions were rarely found. All
in all, bile reflux in the gastric pouch is clinically rele-
vant and the effects of bile-induced chronic inflammation
will be studied in future papers. We propose that all
prospective trials on OAGB should include UGE preop-
eratively, and at 5-year intervals, in order to have data on
the actual effects of bile exposure to the gastric pouch
and esophagus.
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Table 2 Histologic findings in
upper gastrointestinal
endoscopies preoperatively and
6 months after one anastomosis
gastric bypass
UGE finding Preop 6 mo De novo findings at 6mo
Number of patients 40 38 (95%)
Normal 24 (60%) 15 (39.5%)
Anastomosis
Inflammation 7 (18.4%) 7 (18.4%)
Ulcer 4 (10.5%) 4 (10.5%)
Foveolar hyperplasia 1 (2.6%) 1 (2.6%)
Stricture 1 (2.6%) 1 (2.6%)
Stomach/gastric pouch
Gastritis levis 8 (20%)
Foveolar hyperplasia or inflammation 0 8 (21.1%) 5 (13.2%)
Benign polyp 2 (5%) 0 0
HP positive gastritis 3 (7.5%) 0 0
Gastro-esophageal junction
Inflammation 4 (10%) 6 (15%) 6 (15.8%)
Gastric metaplasia 1 (2.5%) 3 (7.5%) 3 (7.9%)
Intestinal metaplasia 1 (2.5%) 0 0
Esophagus
Esophagitis 5 (12.5%) 9 (22.5%) 6 (15.8%)
UGE, upper gastrointestinal endoscopy; Preop, prior to bariatric surgery; 6 mo, 6 months after bariatric surgery;
HP, Helicobacter pylori
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Ethical Approval and Informed Consent All procedures performed in
studies involving human participants were in accordance with the ethical
standards of the institutional research committee and with the 1964
Helsinki declaration and its later amendments or comparable ethical stan-
dards. The trial has been reviewed by ethics committee (HUS/1706/2016)
and approved by research review board (HUS269/2017). The trial is
registered at www.clinicaltrials.gov (Clinical Trials Identifier
NCT02882685).
Informed consent was obtained from all individual participants in-
cluded in the study.
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